Cimzia

Drug Overview
Product Profiles
Cimzia: Crohn's disease
Cimzia: Axial spondyloarthritis (axSpA)
Cimzia: Rheumatoid arthritis (RA)
Cimzia: Psoriatic arthritis (PsA)
Cimzia: Psoriasis

Figure 39: Filgotinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 38: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 4: Sales of Stelara, key branded anti-TNFs, and Entyvio across the US, Japan, and five major EU markets, by drug, 2016–25
Figure 39: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 42: Risankizumab for Crohn’s disease – SWOT analysis
Figure 43: The authors drug assessment summary of risankizumab in Crohn’s disease
Figure 40: The authors drug assessment summary of risankizumab in Crohn’s disease
Figure 7: Price sources and calculations, by country
Figure 44: Risankizumab sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 10: Cimzia for psoriatic arthritis – SWOT analysis
Figure 47: The authors drug assessment summary of upadacitinib in Crohn’s disease
Figure 10: Cimzia for Crohn’s disease – SWOT analysis

Table 1: Cimzia drug profile
Table 2: Cimzia pivotal trial data in Crohn’s disease
Table 3: Cimzia late-phase trial data in Crohn’s disease
Table 4: Cimzia sales for Crohn’s disease across the US, Japan, and Spain, by country ($m), 2016–25
Table 5: Cimzia drug profile
Table 6: Cimzia pivotal trial data in axial spondyloarthritis
Table 7: Cimzia ongoing late-phase trial in axial spondyloarthritis
Table 8: Cimzia drug profile
Table 9: Cimzia pivotal trial data in rheumatoid arthritis
Table 10: Cimzia late-phase trial data in rheumatoid arthritis
Table 11: Cimzia drug profile
Table 12: Cimzia pivotal trial data in psoriatic arthritis
Table 13: Cimzia drug profile
Figure 44: Upadacitinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25